← Leaderboards
Reza Yaesoubi
Yale University
$4,453,169
Attributed
$4,453,169
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,453,169 · 4
By mechanism
R01$3,475,561 · 2
K01$517,724 · 1
R21$459,884 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Frederick Lewis Altice$47,021,698
- Michaela Ann Dinan$4,428,713
- Danilo Bzdok$1,801,713
- Sarah Yip$9,270,561
- Lyuba Azbel$323,321
Others in their field
Top investigators on “Cost”
- Eric S Lander · Whitehead Institute For Biomedical Res$748,368,930
- Richard K. Wilson · Washington University$429,230,873
- Richard A Gibbs · Baylor College Of Medicine$414,258,216
- David R. Weir · University Of Michigan At Ann Arbor$393,741,481
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
Research focus
CostPublic HealthPharmaceutical PreparationsTransmission ProcessPrevalenceAntibioticsResistanceCost EffectiveResourcesDiagnosisIncidencePolicy MakerRecommendationPerformanceScienceInvestigationComputer SimulationGuidelinesQuality-Adjusted Life YearsPredispositionProgramsMortalityHigh PrevalenceAntibiotic Resistance
Grant awards (13)
A clinical decision tool to optimize the selection of antibiotics for patients with rifampicin-resistant Tuberculosis$700,666
R01 · FY2025 · AI · contact PI
A clinical decision tool to optimize the selection of antibiotics for patients with rifampicin-resistant Tuberculosis$647,922
R01 · FY2024 · AI · contact PI
Enhancing surveillance systems to slow the spread of antimicrobial-resistant gonorrhea in the United States$416,735
R01 · FY2024 · AI · contact PI
A decision tool to inform the optimal use of non-pharmaceutical interventions during the COVID-19 pandemic$235,692
R21 · FY2024 · AI · contact PI
Enhancing surveillance systems to slow the spread of antimicrobial-resistant gonorrhea in the United States$416,735
R01 · FY2023 · AI · contact PI
A decision tool to inform the optimal use of non-pharmaceutical interventions during the COVID-19 pandemic$224,192
R21 · FY2023 · AI · contact PI
Enhancing surveillance systems to slow the spread of antimicrobial-resistant gonorrhea in the United States$416,735
R01 · FY2022 · AI · contact PI
Enhancing surveillance systems to slow the spread of antimicrobial-resistant gonorrhea in the United States$416,735
R01 · FY2021 · AI · contact PI
Enhancing surveillance systems to slow the spread of antimicrobial-resistant gonorrhea in the United States$460,033
R01 · FY2020 · AI · contact PI
Improving the control of multidrug-resistant tuberculosis through targeted screening and use of novel anti-tuberculosis drugs$128,628
K01 · FY2019 · AI · contact PI
Improving the control of multidrug-resistant tuberculosis through targeted screening and use of novel anti-tuberculosis drugs$128,628
K01 · FY2018 · AI · contact PI
Improving the control of multidrug-resistant tuberculosis through targeted screening and use of novel anti-tuberculosis drugs$129,444
K01 · FY2017 · AI · contact PI
Improving the control of multidrug-resistant tuberculosis through targeted screening and use of novel anti-tuberculosis drugs$131,024
K01 · FY2016 · AI · contact PI